
Connecticut’s newest privacy law makes a claim that sounds almost strange to read in a legal document: that you own your DNA. Not metaphorically — as a matter of statute, Connecticut residents now hold “a property interest in their biological sample and genetic test results derived from the consumer’s DNA.” It’s a genuinely unusual thing for a legislature to say, since most privacy law treats your genetic information as sensitive data to be protected, not as property you can be said to own the way you own a car or a house. Connecticut isn’t alone this year, either. Since January, five states have enacted new genetic privacy laws, each taking a different approach to the same underlying problem: what happens to your DNA after you spit in the tube.
Five States, One Trigger Year
Utah, South Dakota, Connecticut, Vermont, and Rhode Island have each enacted genetic privacy legislation in 2026, making Rhode Island’s June bill the fifth such law this year by one legal tracker’s count.[1] That is a remarkable amount of legislative activity for a corner of privacy law that, until recently, barely existed as its own category. It didn’t happen in a vacuum. Rhode Island’s law was drafted specifically in response to the gaps exposed by 23andMe’s 2025 bankruptcy — the case this site covered in detail last June, in which a company holding more than 15 million genetic profiles went through Chapter 11 and sold its entire database to a new owner with privacy commitments that were promised but not, at the time, legally binding on anyone.[2] That case became a template for what lawmakers in other states were worried about: DNA data sitting in a private company’s servers with essentially no state or federal rule requiring that company to get your permission before selling it, transferring it, or handing it to someone else.
This site’s earlier overview of genetic genealogy databases and law enforcement access touched briefly on two of this year’s laws — Utah’s and South Dakota’s — as they stood in May 2026. That article focused mainly on the law-enforcement side of genetic privacy: which databases police can search, and under what conditions. This is a different and, in some ways, more consequential story. These five laws are not primarily about crime-solving. They are about the everyday relationship between a consumer and a genetic testing company — Ancestry, 23andMe’s successor, FamilyTreeDNA, MyHeritage, and any other business that collects, stores, or sells DNA data — and what rights, if any, that consumer keeps once the sample has been mailed in.
The Consumer-Consent Model: South Dakota, Vermont, Rhode Island, and Connecticut
Four of this year’s five laws share a common structure, even though each was drafted independently. All four require direct-to-consumer genetic testing companies to obtain “express consent” — an affirmative, specific yes, not something inferred from a person’s failure to opt out — before collecting, using, storing, or sharing genetic data. All four require separate consent for separate purposes: initial testing is one decision, keeping the biological sample in storage is another, sharing data with a third party is a third, and using it for marketing is a fourth. None of the four accept consent obtained through “dark patterns” — interface designs built to trick or pressure someone into agreeing to something they wouldn’t otherwise choose.
South Dakota’s Genetic Data Privacy Act (SB 49), effective July 1, 2026, requires that companies destroy a customer’s biological sample within 30 days of a request, notify consumers when de-identified data is shared for research, and maintain a documented security program. The state’s attorney general can pursue civil penalties of up to $5,000 per violation. The law exempts HIPAA-covered health information, diagnostic samples used for medical treatment, hospitals, and accredited research institutions.[3]
Vermont’s Act 135, also effective July 1, 2026, goes further on a few fronts. It bars companies from sharing genetic data with insurers or employers at all, requires a court warrant (or the consumer’s own informed consent) before government access, and prohibits genetic discrimination against anyone who exercises their privacy rights under the law. Service providers who process genetic data on a company’s behalf can’t repurpose it for their own commercial use or combine it with other data sets, and must destroy it immediately once their contract ends. Consumers have 30 days to revoke consent, and enforcement runs through Vermont’s attorney general as an unfair-trade-practices matter, with a 30-day cure period before a civil case can proceed.[4]
Rhode Island’s Genetic Information Privacy Act (S 2203) was signed by Governor Dan McKee on June 19, 2026, and — unusually — took effect immediately rather than on some future date. Its consent and deletion requirements track the same basic pattern as the other three, but its enforcement mechanism is distinctive: civil penalties, ranging from $1,000 for negligent violations up to $1,000–$10,000 for willful ones, are paid directly to the affected consumer rather than into a state fund. Advocacy from the College of American Pathologists and other groups helped shape the final bill, and lawmakers pointed directly to 23andMe’s bankruptcy as the reason the legislation was needed now rather than later.[2]
Connecticut’s Senate Bill 4 — signed June 1, 2026, with its genetic-data provisions taking effect October 1 — is part of a broader overhaul of the state’s existing data privacy law, expanded this year to cover data brokers, geolocation sales, and algorithmic pricing alongside genetic testing. Its consumer rights largely mirror South Dakota’s and Vermont’s: access, deletion, sample destruction, and consent revocation, enforced exclusively by the state attorney general. What sets Connecticut apart is the property-interest language in the opening paragraph, and a gap that legal commentators have flagged: unlike the other three, Connecticut’s law does not exempt human-subjects research conducted under the federal Common Rule, nor does it carve out HIPAA-covered entities in the same way. Whether that omission was deliberate or simply the product of a broader, faster-moving bill remains an open question — but it means Connecticut’s law reaches further into research and clinical contexts than its counterparts.[5][6]
Utah’s Different Problem: Foreign Adversaries, Not Consumer Consent
Utah’s law is not really part of the same story, even though it gets grouped with the other four in most of the coverage. House Bill 182, which does not take effect until January 1, 2028, has nothing to do with consumer consent forms or deletion requests. It is a national-security measure that restricts genetic sequencing facilities in Utah — hospitals and genomic research centers — from using sequencing equipment or software linked to designated foreign adversary countries, bans storing Utah genetic data in those countries, and requires covered entities to sign sworn statements attesting to compliance. It fits into a broader, separate wave of state and federal concern about foreign access to American biological and genomic data, more closely related to export-control policy than to the privacy-rights model driving the other four states. It is worth knowing about, but it answers a different question: not “can a company sell my DNA data without asking me,” but “can my DNA data end up processed by servers a hostile government can reach.”[7]
The Federal Gap These Laws Are Filling
None of this would be necessary if federal law already covered the ground. It doesn’t, and the gap is wider than most people realize. The Genetic Information Nondiscrimination Act of 2008 — GINA, the one federal law most people have actually heard of in this space — only prohibits health insurers and employers with 15 or more employees from using genetic information in coverage or employment decisions. It says nothing about how a direct-to-consumer testing company collects, stores, sells, or discloses your genetic data in the first place, and it doesn’t touch life insurance, disability insurance, or long-term care insurance at all.[8] A company can comply fully with GINA while still selling your genetic profile to a data broker, a pharmaceutical research partner, or — as 23andMe’s bankruptcy demonstrated — an entirely new corporate owner, without ever being required to ask your permission.
The 23andMe case exposed a second, more technical gap: federal bankruptcy law’s protections for personally identifiable information in corporate asset sales don’t expressly cover genetic data, leaving a hole that 28 state attorneys general and a court-appointed ombudsman all flagged during that proceeding without being able to close it. That combination — no comprehensive federal consumer-privacy law for genetic data, and a bankruptcy code that wasn’t written with DNA profiles in mind — is precisely the vacuum these five state laws are stepping into, one legislature at a time.
Your DNA as Property: A Genuinely New Legal Idea
Connecticut’s property-interest framing deserves a closer look, because it is not simply stronger language for the same old idea. Most privacy statutes — including the other three consumer-consent laws in this year’s wave — treat genetic data as sensitive personal information that a company must handle according to certain rules: get consent, allow deletion, don’t discriminate. Calling something “property,” by contrast, invokes an entirely different area of law, one built around ownership, transfer, and the remedies available when someone takes your property without permission. It’s the kind of language more commonly seen in disputes over land, intellectual property, or physical possessions than in a consumer-privacy statute.
What that property framing will actually mean in practice is genuinely unclear, and honesty requires saying so plainly: Connecticut’s law took effect too recently for any court to have interpreted it, and no case law yet exists testing whether “property interest in your genetic test results” gives a Connecticut resident meaningfully different legal options than a straightforward consent-and-deletion right would. It might turn out to be largely symbolic. It might turn out to open doors — around inheritance, around what happens to a deceased relative’s genetic property, around remedies for unauthorized use — that the other four states’ laws don’t open at all. For now, it’s a legal experiment worth watching, not a settled answer.
What This Means for Dillman Researchers
If you’ve tested with more than one company, you may already have meaningfully different rights depending on where you live and which company you used — and, increasingly, depending on where that company is required to comply regardless of where you live. A national testing company serving customers in South Dakota, Vermont, Connecticut, and Rhode Island generally has to build its consent, deletion, and data-handling processes to satisfy the strictest applicable state law, which in practice tends to extend at least some of those protections to customers elsewhere, even in states with no genetic privacy law of their own. That’s not guaranteed, though, and it’s worth checking directly: log into your account with each company you’ve tested through — AncestryDNA, FamilyTreeDNA, MyHeritage, or 23andMe Research Institute — and look specifically for a genetic-data privacy policy or a data-deletion option, rather than assuming the general privacy policy covers it. The DFA’s Dillman DNA Project page has more on how DNA testing fits into the Association’s broader research, and last June’s law-enforcement-focused overview is still the place to go for questions about who can search your data and under what circumstances, as opposed to what these new laws cover: what a company itself can do with it.
The Patchwork Problem
Five states in one year is genuine momentum, and more bills are reportedly moving through other state legislatures. But five states is also, bluntly, not very many. A resident of the other forty-five states who tests with a DTC genetic company today has none of these specific protections unless that company voluntarily extends them — and voluntary extension, however common it may turn out to be in practice, is not the same thing as a legal right. The patchwork that resulted from Maryland’s and Montana’s earlier law-enforcement-access rules is now being joined by a second, separate patchwork of consumer-consent rules, with different consent structures, different penalty amounts, different exemptions, and — in Connecticut’s case — a genuinely novel legal theory that nobody yet knows the real scope of. A company operating nationally has to track five different rule sets to stay compliant; a consumer moving from Vermont to a state without any of these protections loses rights simply by crossing a state line, in a way that would seem strange if it were happening with almost any other category of legal protection.
The honest conclusion is that this year’s wave of laws is real progress and an unfinished project at the same time. It took a company’s bankruptcy — and the exposure of 6.9 million people’s genetic data — to generate the political will for five states to act in a single year. Whether that will extends to a comprehensive federal law, or whether genetic privacy in America simply continues to depend on which state you happen to live in, is the question this year’s legislative wave raises without answering.
Genetic privacy law is changing quickly. The laws described here are as they stood in September 2026, and amendments, implementing regulations or court rulings may have changed them since.
Sources
- Inside Privacy (Covington & Burling). “Rhode Island Enacts Genetic Privacy Law.” 2026. insideprivacy.com.
- UpriseRI. “Your DNA Now Has Legal Protection in Rhode Island: Here’s What the New Genetic Privacy Law Does.” 2026. upriseri.com.
- Hunton Andrews Kurth, Privacy and Cybersecurity Law Blog. “South Dakota Enacts Genetic Data Privacy Act.” 2026. hunton.com.
- Vermont General Assembly. “Act 135 (2026), As Enacted.” legislature.vermont.gov.
- Mintz. “Connecticut Overhauls Its Privacy Law: What Businesses Need to Know.” June 5, 2026. mintz.com.
- Inside Privacy (Covington & Burling). “Connecticut Enacts Genetic Privacy Law.” 2026. insideprivacy.com.
- Paubox. “Utah and South Dakota Advance Genetic Privacy Rules With New 2026 Laws.” 2026. paubox.com.
- National Human Genome Research Institute. “Genetic Discrimination.” genome.gov (accessed September 2026).
- Dillman Family Association. “Genetic Genealogy Databases, Law Enforcement, and Privacy.” June 3, 2026. dillmanfamilyassociation.org.
Featured image: DNA double helix. Photo by Warren Umoh on Unsplash.
AI Disclosure: This article was researched and written with the assistance of Claude, an AI assistant developed by Anthropic. Online sources were accessed in September 2026.
Discover more from Dillman Family Association
Subscribe to get the latest posts sent to your email.
